“The net loss included non-cash charges of approximately $0.9 million, which consisted of approximately $1.0 million of depreciation and amortization expense, and noncash interest expense, partially offset by $0.3 million gain due to the change in fair value of warrant liabilities.”
“AbbVie's global Imbruvica revenues decreased 25% for the three months ended March 31, 2026 primarily driven by unfavorable pricing and decreased demand in the United States, partially offset by increased collaboration revenues.”
“The growing adoption of generative AI is being driven by the pursuit of cost reduction, value enhancement, differentiated customer engagements, and operational efficiency benefits that we believe are not available to organizations through legacy solutions.”